In this study, we investigated the combined effects of FLT3 TKIs (Gilteritinib or Sorafenib) with Venetoclax, a selective BCL-2 inhibitor, on eliminating FLT3/ITD AML cells. Here, BCL2 is linked to acute myeloid leukemia.